Seer (SEER) Share-based Compensation (IS) (2024 - 2026)
Seer (SEER) posted quarterly Share-based Compensation (IS) of $2.1 million for Q1 2026, down 54.39% year-over-year from $4.7 million in Q1 2025, and down 35.27% quarter-over-quarter from $3.3 million in Q4 2025.
Seer (SEER) Share-based Compensation (IS) (2024 - 2026) Analysis & Trends
Seer's Share-based Compensation (IS) history runs 3 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Share-based Compensation (IS) fell 54.39% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $12.9 million (down 49.08% YoY), while the FY2025 annual figure was $15.4 million, down 45.35% from the prior year.
- Share-based Compensation (IS) for Q1 2026 stood at $2.1 million, down from $3.3 million in the prior quarter.
- The five-year high for Share-based Compensation (IS) was $7.7 million in Q2 2024, with the low at $2.1 million in Q1 2026.
- The 3-year median for Share-based Compensation (IS) is $4.7 million (2025), against an average of $5.1 million.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation (IS) plunged 38.48% in 2025, then plunged 54.39% in 2026.
- Seer's Share-based Compensation (IS) stood at $6.4 million in 2024, then sank by 48.98% to $3.3 million in 2025, then plunged by 35.27% to $2.1 million in 2026.
- Business Quant data shows SEER's Share-based Compensation (IS) at $2.1 million in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Seer | 230.63 Mn | 230.63 Mn | 1.51 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Mn |
| Jun 30, 2026 | 1.56 Mn |
| Mar 31, 2026 | 2.13 Mn |
| Mar 31, 2026 | 2.13 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.59 Mn |
| Sep 30, 2025 | 3.59 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 6.44 Mn |
| Dec 31, 2024 | 6.44 Mn |
| Sep 30, 2024 | 6.52 Mn |
| Sep 30, 2024 | 6.52 Mn |
| Jun 30, 2024 | 7.66 Mn |
| Jun 30, 2024 | 7.66 Mn |
| Mar 31, 2024 | 7.58 Mn |
| Mar 31, 2024 | 7.58 Mn |